Bone metabolism: Molecular mechanisms;Knochenstoffwechsel: Molekulare mechanismen

Zeitschrift fur Rheumatologie

Volumn 66, Issue 4, 2007, Pages 286-289

  Neumann, E ^a   Schett, G ^b,c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Bone metabolism; Osteoblasts; Osteoclasts; Osteoporosis; Remodelling

Indexed keywords

CYTOKINE; GROWTH FACTOR; HORMONE;

ALBERS SCHOENBERG DISEASE; BONE METABOLISM; BONE REMODELING; BONE STRUCTURE; HOMEOSTASIS; HUMAN; MOLECULAR MECHANICS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE AND BONES; BONE REMODELING; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 34447309032     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-007-0182-4     Document Type: Review

References (38)

1. Blumsohn A, Naylor KE, Timm W et al. (2003) Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res 18: 1274-1281
2. Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32: 136-141
3. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342
4. Cao X, Chen D (2005) The BMP signalling and in vivo bone formation. Gene 357: 1-8
5. Catrina AI, af Klint E, Ernestam S et al. (2006) Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54: 76-81
6. Charatcharoenwitthaya N, Khosla S, Atkinson EJ et al. (2007) Effect of blockade of TNF-alpha and Interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 22: 724-729
7. Cohen MM Jr (2006) The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 140: 2646-2706
8. Diarra D, Stolina M, Polzer K et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156-163
9. Dobnig H, Hofbauer LC, Viereck V et al. (2006) Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17: 693-703
10. Glass DA, Karsenty G (2006) Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 73: 43-84
11. Goldring SR (2003) Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 73: 97-100
12. Gravallese EM, Galson DL, Goldring SR, Auron PE (2001) The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 3: 6-12
13. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann N Y Acad Sci 1092: 385-396
14. Hofbauer LC (2006) Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Ann Endocrinol (Paris) 67: 139-141
15. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495
16. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5: 618-625
17. Kotake S, Udagawa N, Takahashi N et al. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103: 1345-1352
18. Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209
19. Lacey DL, Timms E, Tan HL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176
20. Lam J, Takeshita S, Barker JE et al. (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488
21. Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44: 1546-1548
22. Lee SK, Gardner AE, Kalinowski JF et al. (2006) RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38: 678-685
23. Li P, Schwarz EM, O'Keefe RJ et al. (2004) RANK signalling is not required for TNF-alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF-alpha-mediated inflammatory arthritis. J Bone Miner Res 19: 207-213
24. Liu XH, Kirschenbaum A, Yao S, Levine AC (2006) Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann N Y Acad Sci 1068: 225-233
25. Okamoto M, Murai J, Yoshikawa H, Tsumaki N (2006) Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 21: 1022-1033
26. Pasco JA, Kotowicz MA, Henry MJ et al. (2006) High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 296: 1353-1355
27. Ritchlin CT, Haas-Smith SA, Li P et al. (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821-831
28. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367: 2010-2018
29. Sato K, Suematsu A, Okamoto K et al. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673-2682
30. Schett G, Kiechl S, Weger S et al. (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166: 2495-2501
31. Seibel MJ (2006) Clinical application of biochemical markers of bone turnover. Arq Bras Endocrinol Metabol 50: 603-620
32. Takayanagi H, Ogasawara K, Hida S et al. (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408: 600-605
33. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289: 1504-1508
34. Dijke P ten (2006) Bone morphogenetic protein signal transduction in bone. Curr Med Res Opin (Suppl 1) 22: S7-S11
35. Vis M, Havaardsholm EA, Haugeberg G et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1495-1499
36. Wei S, Kitaura H, Zhou P et al. (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115: 282-290
37. Wong PK, Quinn JM, Sims NA et al. (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54: 158-168
38. Yoshida H, Hayashi S, Kunisada T et al. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345: 442-444